Skip to main navigation
Skip to search
Skip to main content
Oregon Health & Science University Home
Help & FAQ
Home
Profiles
Research units
Core Facilities
Publications
Search by expertise, name or affiliation
Apixaban to Prevent Recurrence after Cryptogenic Stroke in Patients with Atrial Cardiopathy the ARCADIA Randomized Clinical Trial
ARCADIA Investigators
Neurology
Research output
:
Contribution to journal
›
Article
›
peer-review
5
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Apixaban to Prevent Recurrence after Cryptogenic Stroke in Patients with Atrial Cardiopathy the ARCADIA Randomized Clinical Trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
apixaban
100%
Stroke
49%
Randomized Controlled Trials
48%
Recurrence
41%
Atrial Fibrillation
38%
Intracranial Hemorrhages
16%
Random Allocation
14%
Medical Futility
10%
Hemorrhage
9%
Phase III Clinical Trials
8%
Brain Natriuretic Peptide
7%
National Institutes of Health (U.S.)
7%
Secondary Prevention
7%
Lead
6%
Electrocardiography
5%
Health Care Outcome Assessment
4%
Safety
4%
Serum
3%
Therapeutics
1%